I was recently reading about the technological advances in the field of footwear and shoes is that there are some very interesting out there walking. Encimita Thus there are some that make you feel like you're walking on clouds (Air Max NIKE), ones that come with built-in GPS technology allows someone to track the whereabouts and to send an alert if that person leaves the predetermined area (GTX Corporation), other regulating body temperature and avoid odors (Brooks HVAC) and up to that promise spiritual balance and holistic benefits (Nuala Puma Chapora). And I mean walked in thong ...
Given my insatiable entrepreneurial spirit and my fervent desire to contribute to humanity I have decided to launch a new concept of shoes.
How it works: before leaving the house a program, using the GPS shoes make a list of turns that have to do and trace a route. That way one chooses the right places to avoid. Thus, one leaves the house to the bank and the shoes know where to go to get there more quickly, avoid puddles and sidewalks in disrepair. Once the bank goes into the shoe "longline" and through a special micro-massaging foot roller for one not to get tired waiting in line.
Just leave a bank, the shoe is automatically directed to the next round and if you try to deviate, the shoes have a function "Plomi-step" which put heavy as lead and difficult to walk. If one gives them and try to remove them from clever to go barefoot, soles use "Pecuec-mist" that releases a foul-smelling haze embarrasses anyone.
Programming can be done weekly, monthly and yearly so as to provide for the Sunday lunches where Aunt and obligations as masses, birthday parties, anniversaries and other social and family commitments.
And as more users use the network to record their movements will be possible to cross-reference and choose routes that are likely to find me my friends or where it is unlikely that I find my ex-boyfriend. It may even offer services for singles who want to run into (literally) with potential partners with customers and vendors as possible. And if prevention fails and an encounter unwanted happens, the soil releases scents painkillers.
In appearance, the shoes would obviously have the technology and would puff the super chic, fully customizable and also come out with all thanks to technology Microfiber Cameleon makes the shoe changes color according to the pants or purse, according to taste the user.
The possibilities are endless. I already got the vision, just need someone to put science.
The Brown Bag Lunch at the North Platte Public Library today at noon will have a touch of culture from the east. Terri Johnson, a computer technology assistant at the library, will be sharing photos and stories from her two trips to Japan in the '90s.
Johnson's contact with Japan began with her family hosting Japanese exchange students as part of a 4-H program. She is calling her presentation "A Look Back at Japan."
Johnson took two trips to Japan, each three weeks long. She went to the country first in 1994 and again in 1999. The trips were to visit families of students who had stayed with Johnson in the exchange program. For Johnson the experience of the trip was unique because she got to live with families as opposed to having a tourist experience. The people of Japan impressed her.
"How friendly people were, how generous people were and how patient they were," Johnson said. "What I remember most is becoming part of their family."
The contrast of the old and the new in Japan also impressed Johnson. She explained during her trip she visited buildings nearly 700 years old, next to modern buildings. The trip to Japan and taking exchange students into her home was just a part of something bigger for Johnson.
It wasn't just one family Johnson stayed with, but a number of families. She explained during her trip she stayed with a Buddhist priest and with a family in public housing.
The trip was also about learning new things. Johnson said she learned how to do a tea ceremony during her stay in Japan. The tea ceremony is a ceremonial way of preparing and drinking tea influenced by Buddhist traditions in Japan.
There were a number of unique restaurants Johnson experienced during her visit. She talked about a sushi restaurant where plates passed around on a conveyer belt and patrons took plates off the belt as they passed. When patrons finished their meals they were charged based on the number, and the color of the plates. She said there was also a restaurant operating like a buffet, but where diners had to pay for the amount of time they spent eating.
During her trip she tried new foods, such as fried eel and octopus pizza.
Johnson spoke little Japanese, but said communication with people in Japan wasn't a problem.
A phase III study of the anti-CD3 drug oteliximab in 240 newly diagnosed type 1 diabetes patients also produced negative findings. The dose – one-sixteenth of that used in previous trials – had been chosen to reduce adverse events seen previously, particularly Epstein-Barr virus activation. The low dose was not effective in preserving C-peptide. This study, dubbed DEFEND, was funded by Tolerx, with support from the Juvenile Diabetes Research Foundation.
"This is clearly an important pathway. Further studies will try to increase that dosage to duplicate the previous efficacy with fewer side effects," said Dr. Peter Gottlieb, professor of medicine and pediatrics at the University of Colorado, Denver.
Another compound under study, DiaPep277, was developed with the goal of preventing beta-cell destruction. Created by the removal of 24 of 500 amino acids from a "heat shock" protein involved in beta-cell destruction via T-cell activation, DiaPep277 had been shown to change destructive T cells into cytokine-secreting protective T-cells in mouse models of type 1 diabetes.
In one phase II study, injections of DiaPep277 in 100 newly diagnosed patients with type 1 diabetes preserved beta-cell insulin secretion for up to 2 years following diagnosis, said Dr. Itamar Raz, professor of medicine and director of the Hadassah Diabetic Center in Jerusalem, Hadassah Hebrew University Hospital.
DiaPep277 is currently in two phase III trials in which beta-cell function, insulin use, and glucose control are being monitored as key outcomes in more than 450 patients per trial. Results for one of the studies are expected by early next year, Dr. Raz said.
Dr. Skyler is an advisory panel and/or board member for a long list of companies that make diabetes-related products. He holds stock in and/or is a shareholder of Amylin Pharmaceuticals, Circulat Biotech, Dexcom, Ideal Life, Inspire Pharmaceuticals, Moerae Matrix, and Tandem Diabetes Care.
Dr. Gitelman and Dr. Sherry stated that they have no disclosures. Dr. Orban serves on the data safety monitoring board for Osiris Therapeutics and is a founding member of Orban Biotechs LLC. Dr. Gottlieb receives research funding from Tolerx, GlaxoSmithKline, MacroGenics, and Diamyd. He has consulted for Eli Lilly, Sanofi-Aventis, and Genentech.